Arbutus Biopharma (ABUS) Assets Average (2010 - 2026)

Arbutus Biopharma's Assets Average history runs 17 years deep, the most recent figure standing at $185.9 million for Q1 2026.

• In Q1 2026, Assets Average rose 49.48% year-over-year to $185.9 million; the TTM figure through Mar 2026 stood at $185.9 million (up 49.48% YoY), while the FY2025 annual figure was $113.2 million, down 18.03% from the prior year.
• Assets Average came in at $185.9 million for Q1 2026 at Arbutus Biopharma, up from $96.2 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $226.4 million in Q2 2022 to a low of $96.2 million in Q4 2025.
• A 5-year average of $162.3 million and a median of $155.2 million in 2024 frame the typical range for Assets Average.
• Across the five-year window, Assets Average jumped 60.76% in 2022 and tumbled 33.12% in 2025, its largest moves.
• Arbutus Biopharma's Assets Average stood at $199.6 million in 2022, then fell by 24.09% to $151.5 million in 2023, then decreased by 10.19% to $136.1 million in 2024, then declined by 29.33% to $96.2 million in 2025, then soared by 93.31% to $185.9 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $185.9 million, $96.2 million, and $100.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison